Stifel Reiterates Buy Rating on Evolus (EOLS)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/13/2026
- S&P 500, Nasdaq futures decline as US-Iran escalation rattles sentiment
- Oil gains over 2% as fresh military strikes threaten Hormuz shipments
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Former emir of Qatar, Sheikh Hamad bin Khalifa Al Thani, dies at 74
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- JPMorgan analysts name top short ideas for third quarter 2026
- The real reason Meta shares are surging has nothing to do with its new AI model
- Apple sues OpenAI, two former employees for trade secrets theft
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company’s Guidance
January 21, 2025 8:00 AM ESTExpects U.S. Approval Within 90 Days for Evolysse Form and Evolysse Smooth Injectable Hyaluronic Acid Gels
Provides 2025 Guidance and Maintains Projection for Full-Year 2025 Profitability1
Preliminary Unaudited Net Revenue of $79.0 Million for the Fourth Quarter 2024, Representing 30% Growth Over the Prior Year Preliminary Unaudited Net Revenue of $266.3 Million for the Full-Year 2024, Representing 32% Growth Over the Prior Year and at the Top of the Companys Guidance Expects U.S. Food and Drug Administration (FDA) Approval Within 90 Days for Evolysse Form and Evolysse Smooth Injectable... MoreEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 17, 2025 4:05 PM ESTNEWPORT BEACH, Calif.--(BUSINESS WIRE)-- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in January of an aggregate of 15,332 restricted stock units (RSUs) of the companys common stock to 6 newly hired... More
